Malecare introduces app for cancer tracking

Cara Livernois | | Health Exec | Precision Medicine

Malecare, a nonprofit organizations aiding in the treatment of men’s cancer, has released its Cancergraph mobile application for the tracking of symptoms.

The newly unveiled app is available on iOS products to help provide the most personalized and efficient care to patients through documentation of their own experiences. The app gives patients the options to choose from over 200 symptoms and side effects, including cancer type and current medications. They can also take and upload pictures into a secure storage area that can then be shared with their physicians. A journal function also allows for more in-depth notes on cancer symptoms.

"For anyone who is going through cancer this is an invaluable tool," said Darryl Mitteldorf, founder of Malecare. "The ability to accurately keep track of symptoms and side effects changes cancer care for both the patient and doctor."

 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.